biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > 5 business days until the expiry of the J&J option

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Jan 24, 2023 2:46pm

117 Views

Post# 35242979

RE:5 business days until the expiry of the J&J option

J&J is the largest healthcare company in the world and its moves are watched closely by industry and the media

So then i would have to believe if xb3 had any value, after JNJ's evaluation, then they would not let the option expire and they would be moving forward with some sort of extension, right? LOL

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Jan. 10, 2025)